Articles

BioMarin Drug Acquisition and Study Setback: Implications for Pharma

BioMarin's recent drug study setback raises critical questions for the pharmaceutical industry. This article explores the implications for business development and investment strategies.

Canadian Medical Societies and Conflict-of-Interest Policies: A Critical Review

A recent study highlights the lack of robust conflict-of-interest policies among Canadian medical societies, raising concerns for pharmaceutical stakeholders. This article explores the implications for the industry.

Marc Tessier-Lavigne Responds to Allegations in New Book

Marc Tessier-Lavigne addresses serious allegations from a new book regarding his conduct in the Stanford misconduct case, raising important questions for the pharmaceutical industry.

No Surprises Act: Spine Surgery Costs Skyrocket

This article examines the dramatic increase in spine surgery costs due to the No Surprises Act arbitration, highlighting key implications for the pharmaceutical sector.

FDA Shakeup: Høeg Fired Amid Amgen Drug Controversy

This article analyzes the recent firing of Høeg from the FDA and the tragic deaths linked to an Amgen drug, highlighting key implications for the pharma industry.

Amgen Defends Tavneos Amid Japan Liver Toxicity Concerns

Amgen continues to support its rare disease drug Tavneos despite a liver toxicity report from Japan. This article explores the implications for the pharmaceutical industry.

FDA's Unreleased Covid Vaccine Deaths Report: What You Need to Know

This article delves into the recently published report on Covid vaccine deaths by the FDA, highlighting its implications for the pharmaceutical industry.

Palvella's Nasdaq Uplisting: Implications for Rare Disease Development

Palvella Therapeutics has achieved a significant milestone by earning a spot on a stricter Nasdaq tier, signaling growth potential in the rare disease sector. This article analyzes the implications for investors and pharma teams.

Britain's Tobacco Regulation: Lessons from Massachusetts

This article examines Britain's adoption of Massachusetts tobacco regulations and the potential implications for the pharmaceutical sector.

STAT+ R&D Performance Rankings: Insights for Pharma Leaders

Discover the latest STAT+ rankings of pharma companies based on R&D performance and what it means for the industry landscape.

Supreme Court's Impact on Pharma Pricing Strategies

The Supreme Court's recent decision not to hear IRA challenges from Novo and AstraZeneca could reshape drug pricing strategies. This article explores the implications for pharma executives and investors.

Supreme Court Setback for Pharma and TrumpRx Expansion Insights

This article discusses the recent Supreme Court setback for the pharmaceutical industry and the expansion of TrumpRx, providing key insights for B2B readers.

Migraine Drugmaker's Public Market Move: Insights from a Reverse Merger

A migraine drugmaker is making waves by heading to the public markets through a reverse merger. This article explores the implications for the pharmaceutical industry.

Canadian Medical Societies' Conflict-of-Interest Policies Under Scrutiny

A recent study highlights the inadequacy of conflict-of-interest policies in Canadian medical societies, raising concerns for the pharmaceutical industry. This article explores the implications for pharma teams and stakeholders.

The Financial Implications of Spine Surgery Under the No Surprises Act

This article examines the stark contrast in spine surgery costs due to the No Surprises Act arbitration, highlighting implications for the pharmaceutical industry.

Wave Aims for Monthly Dosing with RNA Editing for AATD

Wave is advancing its RNA editing treatment for AATD, targeting a monthly dosing regimen. This development could reshape treatment paradigms in the pharmaceutical industry.

Understanding the No Surprises Act: Spine Surgery Costs Explode

This article delves into the dramatic cost increase of spine surgery under the No Surprises Act, highlighting implications for pharmaceutical businesses.

Novartis Ends Contract with Porton: Legal Implications and Market Impact

Novartis has terminated its contract with Chinese CDMO Porton, raising significant legal and market implications. This article explores the fallout and what it means for the pharmaceutical industry.

Impact of 600 New Generic Meds on Pharma Purchasing

The White House has added 600 generic medications to the TrumpRx purchasing portal, signaling significant changes in the pharmaceutical landscape. This article explores the implications for pharma teams and investors.

The Significance of the WakeMed – Atrium Health Merger

This article delves into the WakeMed – Atrium Health merger, highlighting its significance for the pharmaceutical sector and business development teams.